Treatment Options for Locally Advanced or Metastatic Primary Liver Cancer

Transarterial embolization (TAE) and transcatheter arterial chemoembolization (TACE) in patients with nonmetastatic disease.

First-line systemic therapy.

First-line systemic therapy.

Combination immunotherapy and targeted therapy.

First-line systemic therapy. › Combination immunotherapy and targeted therapy.

Atezolizumab and bevacizumab.

First-line systemic therapy. › Combination immunotherapy and targeted therapy.

Atezolizumab and cabozantinib.

First-line systemic therapy.

Combination immunotherapy alone.

First-line systemic therapy. › Combination immunotherapy alone.

Doublet immune checkpoint inhibitors.

First-line systemic therapy. › Combination immunotherapy alone.

Single-agent immune checkpoint inhibitors.

First-line systemic therapy.

Targeted therapy (multikinase inhibitors).

First-line systemic therapy. › Targeted therapy (multikinase inhibitors).

Lenvatinib.

First-line systemic therapy. › Targeted therapy (multikinase inhibitors).

Sorafenib.

Second-line systemic therapy.

Second-line systemic therapy.

Targeted therapy (multikinase inhibitors).

Second-line systemic therapy. › Targeted therapy (multikinase inhibitors).

Regorafenib.

Second-line systemic therapy. › Targeted therapy (multikinase inhibitors).

Cabozantinib.

Second-line systemic therapy. › Targeted therapy (multikinase inhibitors).

Ramucirumab.

Second-line systemic therapy.

Combination immunotherapy and immunotherapy alone.

Second-line systemic therapy. › Combination immunotherapy and immunotherapy alone.

Pembrolizumab.

Second-line systemic therapy. › Combination immunotherapy and immunotherapy alone.

Nivolumab and ipilimumab.

Second-line systemic therapy. › Combination immunotherapy and immunotherapy alone.

Nivolumab.

Radiation therapy.